Looking out on the event horizon of small ligand discovery for nuclear receptors, it is noteworthy that LXR and FXR agonists are in development for treating non-alcoholic steatohepatitis and preventing atherosclerosis [108]. The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatohepatitis.